Growth oriented life sciences company specializing on psychedelics Lobe Sciences Ltd (CSE: LOBE) (OTC: GTSIF) has appointed Professor Benjamin Kelmendi to its scientific advisory board. Professor Kelmendi serves as an assistant Professor in the Department of Psychiatry at the Yale University School of Medicine.
The Professor is currently carrying out a study to find out the effects of psilocybin on the neurocircuitry implicated development, maintenance and treatment of patients with obsessive-compulsive disease.
Other than being an assistant Professor Dr. Kelmendi also adds up as also a co-founder of the Yale Psychedelic Science Group is also a board certified psychiatrist
This announcement was made by the company’s chief executive and director Philip Young who stated how the company is delighted to welcome Dr. Kelmendi who will bring with him a lot of relevant experience to Lobe.
“We are extremely pleased to welcome Ben to our Scientific Advisory Board. Dr. Kelmendi will add significant relevant experience to the team as we move through preclinical studies into human clinical trials. We look forward to working with Dr. Kelmendi and the team at the Yale Psychedelic Science Group,” said Young.
